Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Cr&eacut...
Saved in:
Main Authors: | Pujals A, Favre L, Gaulard P, Wiels J |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/fd36db5f774b4124b36b99645b5e827a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
by: Provencio M., et al.
Published: (2011) -
Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
by: Flowers CR, et al.
Published: (2012) -
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
by: Farina F, et al.
Published: (2014) -
Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
by: John R. Krause, et al.
Published: (2021) -
Advances in the diagnosis and management of lymphoma
by: Matasar MJ, et al.
Published: (2012)